ERLOTINIB相关论文
Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on er
Non-small cell lung cancer (NSCLC) is often characterized by an underlying mutation in the epidermal growth factor recep......
...
AntiEGFR-G6-COOH dendrimers loaded with erlotinib to improve its drug resistance and anticancer effi
Erlotinib is an-EGFR-specific TKI that functiones as an antiproliferative agent and is an inducer of apoptosis and rever......
A novel strategy based on chemical-armed singlet oxygen for rationally enhancing small molecular-tar
Objective Cancer is defined as the second leading cause of death and has become a huge global health burden.The discover......
目的 we design the study aiming at detecting the pharmacokinetic difference among gefitinib,icotinib,erlotinib,and OSI-4......
Superior Outcomes of 1st line EGFR TKI in Next-generation Sequencing Identified Uncommon EGFR exon 1
Objective First line EGFR-TKI showed promising efficacy on EGFR mutant advanced nonsmall cell lung cancers(NSCLC)....
A single center, single arm and Phase Ⅱ clinical trail: the study of efficacy and safety of pulsatil
Objective: To observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanc......
A validation LC-MS/MS method for quantification of erlotinib in human plasma and its application for
The object of this study was to develop and validate a simple and reliable LC-MS/MS method for quantitation of erlotinib......
Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confir
Mer is a receptor tyrosine kinase (RTK) with oncogenic properties that is often overexpressed or activated in various ma......
Objective: Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)therapy is considered as one of the most ......
Phase Ⅲ trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the l
Objective: Treatment options for pts with advanced SCC of the lung progressing after platinum-based chemotherapy are lim......
Aim:Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal growth factor receptor (EGFR)......
An Epidermal Growth Factor Receptor-Targeted and Endoplasmic Reticulum-Localized Organic Photosensit
The endoplasmic reticulum(ER),as the largest organelle in eukaryotic cells,plays complex but pivotal roles in multiple i......
Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin h
...
目的 探讨CD146对获得性Erlotinib耐药肺腺癌细胞上皮-间充质转化(EMT)的作用及机制.方法 采用不同浓度的Erlotinib作用于肺腺癌细......
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinica
...
Therapy-related myeloid leukemia during erlotinib treatment in a non-small cell lung cancer patient:
BACKGROUND Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)are tolerable drugs used for patients w......
Tyrosine kinase inhibitors (TKI) has brought revolutionary change for the treatment of lung adenocarcinoma, and the ......
目的:探讨厄洛替尼在营养不良状态大鼠体内药动学特征.方法:建立营养不良状态大鼠模型.模型组和正常对照组分别尾静脉注射厄洛替尼......
目的：观察吉西他滨联合厄洛替尼治疗晚期胰腺癌的临床效果，为晚期胰腺癌的二线治疗方案提供依据。方法112例晚期胰腺癌患者随机分为......
目的探讨放射治疗联合厄洛替尼治疗老年局部晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法选取2015年8月至2016年2月运城市中心......
1例表皮生长因子受体阳性的初诊78岁男性肺癌患者接受厄洛替尼150 mg,1次/d口服化疗。化疗前丙氨酸转氨酶(ALT)12 U/L,天冬氨酸转......
厄洛替尼为表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),临床用于治疗非小细胞肺癌.间质性肺疾病(ILD)是厄洛替尼严重而少见的不......
目的观察厄洛替尼联合卡培他滨方案一线治疗局部晚期或伴转移的胰腺癌的疗效和安全性。方法将40例未接受过全身化疗的局部晚期或伴......
Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent
A selective and sensitive competitive enzyme-linked immunosorbent assay (ELISA) method was developed and validated for t......
目的观察分析厄洛替尼联合调强放疗治疗局部进展期胰腺癌的疗效和安全性。方法回顾性分析23例局部进展期胰腺癌患者的临床资料，治疗......
目的探讨厄洛替尼在脂多糖（lipopolysaccharide，LPS）诱导的小鼠急性肺损伤（acute lung injury，ALI）中的作用及对肺表面活性物质相关蛋白A......
目的观察葡萄糖调节蛋白78(glucose-regulated protein 78,GRP78)对EGFR L858R突变的非小细胞肺癌对erlotinib敏感性的影响,为最终......
近几年,表皮生长因子受体(epidermal growth factor receptor,EGFR)是肿瘤学药物研发的一个重要靶点。EGFR的小分子抑制剂(tyrosin......
尽管一项多中心临床Ⅲ期试验表明在晚期非小细胞肺癌维持治疗中厄洛替尼联用贝伐珠单抗对比贝伐珠单抗单用可增加无进展生存期,但......
本试验建立并验证了测定肿瘤模型BALB/c裸鼠血浆中表皮生长因子受体抑制剂埃罗替尼血药浓度的高效液相色谱方法.使用液液萃取的方......
单独使用表皮生长因子受体类酪氨酸激酶抑制剂(EGFR-TKI)对EGFR野生型非小细胞肺癌(NSCLC)进行治疗,其药效不显著.本研究目的是对......
本试验建立了一种简单快速灵敏的液质联用方法,用以同时测定裸鼠血浆内埃罗替尼及其活性代谢物OSI-420的浓度.采用液液萃取法从血......
原发性肝癌(以下简称肝癌)是世界第六位常见的恶性肿瘤。根据GLOBOCAN 2002年统计结果，全世界每年的肝癌新发例数为62.6万，其中我国......
,Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small
...
...
...
,Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltra
UDP-glucuronosyltransferase 1A1 (UGT1A1) plays a key role in detoxification of many potentially harmful compounds and dr......
目的观察厄洛替尼联合放射线对MKN45细胞的影响,初步探讨厄洛替尼对其放射增敏机制。方法通过MTT法检测厄洛替尼、5-氟尿嘧啶(5-Fu......
目的比较表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)与化疗二线治疗晚期非小细胞肺癌的有效性和安全性。方法检索Cochrane Libr......
Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small c
Background A retrospective analysis of clinical data were conducted reviewing patients who were given erlotinib at Pekin......
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure
Background Several clinical trials showed that erlotinib was effective after the failure of gefitinib in advanced non-sm......
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinica
Background Serum expression of cytokines may provide information about the clinical outcome of advanced non-small cell l......
Initial Progression-Free Survival affer Non-First Line TKIs Therapy Potentially Guides Immediate Tre
Objective The standard therapy aft er failure of the initial non-fi rst line epidermal growth factor receptor tyrosine k......
Effect of application of markers and immune function of patients with tumor of erlotinib combined wi
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
目的探讨厄洛替尼2线或3线治疗化疗失败晚期非小细胞肺癌（NSCLC）的疗效及不良反应。方法收集2008年3月至2010年6月化疗失败的ⅢB／Ⅳ期......
目的 探讨厄洛替尼对ⅢA期非小细胞肺癌(NSCLC)患者手术切除率和肺癌根治率及术后并发症的影响.方法 31例ⅢA期肺癌患者入A组(厄洛......
Initial Progression-Free Survival affer Non-First Line TKIs Therapy Potentially Guides Immediate Tre
Objective The standard therapy aft er failure of the initial non-fi rst line epidermal growth factor receptor tyrosine k......
